Evidence of extensive cellular immune response after SARS-CoV-2 vaccination in ocrelizumab-treated patients with multiple sclerosis

BACKGROUND: Patients with multiple sclerosis receiving ocrelizumab-treatment are in desperate need of a protection against SARS-CoV-2 infection. METHODS: In this study, Euroimmun semi-quantitative Anti-SARS-CoV-2 IgG for detection of humoral response and ELISpot assays for detection of SARS-CoV-2-sp...

Descripción completa

Detalles Bibliográficos
Autores principales: Pompsch, Mosche, Fisenkci, Neslinur, Horn, Peter A., Kraemer, Markus, Lindemann, Monika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606235/
https://www.ncbi.nlm.nih.gov/pubmed/34802469
http://dx.doi.org/10.1186/s42466-021-00158-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606235/
https://www.ncbi.nlm.nih.gov/pubmed/34802469
http://dx.doi.org/10.1186/s42466-021-00158-5

Ejemplares similares